1199802-19-1Relevant articles and documents
Discovery of MK-4409, a novel oxazole FAAH inhibitor for the treatment of inflammatory and neuropathic pain
Chobanian, Harry R.,Guo, Yan,Liu, Ping,Chioda, Marc D.,Fung, Selena,Lanza, Thomas J.,Chang, Linda,Bakshi, Raman K.,Dellureficio, James P.,Hong, Qingmei,McLaughlin, Mark,Belyk, Kevin M.,Krska, Shane W.,Makarewicz, Amanda K.,Martel, Elliot J.,Leone, Joseph F.,Frey, Lisa,Karanam, Bindhu,Madeira, Maria,Alvaro, Raul,Shuman, Joyce,Salituro, Gino,Terebetski, Jenna L.,Jochnowitz, Nina,Mistry, Shruti,McGowan, Erin,Hajdu, Richard,Rosenbach, Mark,Abbadie, Catherine,Alexander, Jessica P.,Shiao, Lin-Lin,Sullivan, Kathleen M.,Nargund, Ravi P.,Wyvratt, Matthew J.,Lin, Linus S.,Devita, Robert J.
, p. 717 - 721 (2014)
We report herein the identification of MK-4409, a potent and selective fatty acid amide hydrolase (FAAH) inhibitor. Starting from a high throughput screening (HTS) hit, medicinal chemistry efforts focused on optimizing of FAAH inhibition in vitro potency,
PYRAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH
-
, (2010/01/07)
The present invention is directed to certain imidazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and t
